Ali Tehrani
Founder chez Student Biotechnology Network
Fortune : 3 M $ au 31/03/2024
Profil
Ali Tehrani was the founder of Zymeworks BC, Inc. where he held the title of President, Chief Executive Officer & Director from 2003 to 2022.
He is also the founder of Student Biotechnology Network.
Currently, Dr. Tehrani is a Director at BIOTECanada, Consortium Québécois sur la Découverte du Médicament, Creatus Biosciences, Inc., Reverb Therapeutics, Amplitude Ventures, and a Board Member at Qurcan Therapeutics, Inc. In the past, he served as the President & Chief Executive Officer of Zymeworks, Inc. from 2013 to 2022 and was a Council Member at Premier's Technology Council from 2016 to 2018.
Dr. Tehrani obtained a doctorate degree from the University of British Columbia in 2003 and undergraduate and graduate degrees from the University of Massachusetts in 1994 and 1996 respectively.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ZYMEWORKS INC.
0,45% | 11/10/2023 | 315 836 ( 0,45% ) | 3 M $ | 31/03/2024 |
Postes actifs de Ali Tehrani
| Sociétés | Poste | Début |
|---|---|---|
| Student Biotechnology Network | Founder | - |
Consortium Québécois sur la Découverte du Médicament
 Consortium Québécois sur la Découverte du Médicament Miscellaneous Commercial ServicesCommercial Services Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann. | Director/Board Member | - |
Creatus Biosciences, Inc.
 Creatus Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Creatus Biosciences, Inc. operates as an industrial biotechnology company specializing in yeast genetic design and development. The company was founded in 2014 and is headquartered in Vancouver, Canada. | Director/Board Member | 01/01/2015 |
BIOTECanada
 BIOTECanada BiotechnologyHealth Technology BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada. | Director/Board Member | 03/06/2021 |
Amplitude Ventures
 Amplitude Ventures Investment ManagersFinance Amplitude Ventures is a venture capital firm. The firm was founded in 2018. It’s headquartered in Montreal, Canada. | Private Equity Investor | 01/03/2022 |
| Reverb Therapeutics | Director/Board Member | 01/07/2023 |
| Qurcan Therapeutics, Inc. | Director/Board Member | 01/01/2022 |
Anciens postes connus de Ali Tehrani
| Sociétés | Poste | Fin |
|---|---|---|
Zymeworks BC, Inc.
 Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Founder | 15/01/2022 |
| ZYMEWORKS INC. | Chief Executive Officer | 15/01/2022 |
| ░░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Ali Tehrani
| University of British Columbia | Doctorate Degree |
| University of Massachusetts | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ZYMEWORKS INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
Zymeworks BC, Inc.
Zymeworks BC, Inc. BiotechnologyHealth Technology Zymeworks BC, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of biotherapeutics. Its product, ZW25 and ZW49, are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
| Premier's Technology Council | Government |
LifeSciences British Columbia
 LifeSciences British Columbia BiotechnologyHealth Technology LifeSciences British Columbia is a non-profit organization, which engages in supporting and representing the life science community through leadership, investment, advocacy, and promotion. It ensures that no life sciences sector is working in isolation and that all sectors come together in a comprehensive, complementary, and coordinated fashion. The company is headquartered in Vancouver, Canada. | Health Technology |
BIOTECanada
BIOTECanada BiotechnologyHealth Technology BIOTECanada serves as a national association for Canada's health, industrial and agricultural biotechnology sectors. The company was founded in 1986 and is headquartered in Ottawa, Canada. | Health Technology |
| Student Biotechnology Network | |
Consortium Québécois sur la Découverte du Médicament
Consortium Québécois sur la Découverte du Médicament Miscellaneous Commercial ServicesCommercial Services Consortium Québécois sur la Découverte du Médicament (CQDM) is a not-for-profit biopharmaceutical research consortium based in Montréal, Canada. CQDM's mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. CQDM funds the development of innovative tools and technologies that accelerate the discovery and development of safer and more effective drugs. The company's Quantum Leap pharma-led funding program for drug discovery research helps SMEs or Canadian universities achieve innovative translational biopharmaceutical research projects. CQDM's SynergiQC-International program is designed to promote university-based industrial research in the biopharmaceutical field with collaborators outside, that will generate economic benefits. The non-profit company was founded by Max Fehlmann. | Commercial Services |
Creatus Biosciences, Inc.
Creatus Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Creatus Biosciences, Inc. operates as an industrial biotechnology company specializing in yeast genetic design and development. The company was founded in 2014 and is headquartered in Vancouver, Canada. | Commercial Services |
Amplitude Ventures
Amplitude Ventures Investment ManagersFinance Amplitude Ventures is a venture capital firm. The firm was founded in 2018. It’s headquartered in Montreal, Canada. | Finance |
| Reverb Therapeutics | |
| Qurcan Therapeutics, Inc. |
